Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs.

Trial Profile

The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Antihyperglycaemics
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LANTUSTITR
  • Sponsors Sanofi

Most Recent Events

  • 25 Aug 2011 Additional drug company added in associations field as reported by European Clinical Trials Database record.
  • 28 Jan 2009 Actual patient numbers (4) added as reported by ClinicalTrials.gov.
  • 28 Jan 2009 Actual initiation date changed from May 2006 to Sep 2006 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top